Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Sectoral/ Thematic median (250 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 18 Sep 2024 – 20 Aug 2026, limited by Axis Consumption Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | Axis Consumption Fund | Nifty 500 |
|---|---|---|
| 18 Sep 2024 | ₹100.00 | ₹100.00 |
| 15 Nov 2024 | ₹92.26 | ₹91.90 |
| 13 Jan 2025 | ₹90.38 | ₹88.89 |
| 12 Mar 2025 | ₹84.13 | ₹84.79 |
| 10 May 2025 | ₹89.68 | ₹90.70 |
| 07 Jul 2025 | ₹94.94 | ₹98.55 |
| 04 Sep 2025 | ₹99.11 | ₹95.49 |
| 01 Nov 2025 | ₹98.51 | ₹99.21 |
| 29 Dec 2025 | ₹96.83 | ₹99.09 |
| 26 Feb 2026 | ₹94.05 | ₹98.12 |
| 25 Apr 2026 | ₹89.78 | ₹94.44 |
| 23 Jun 2026 | ₹91.57 | ₹96.29 |
| 20 Aug 2026 | ₹96.92 | ₹98.39 |
| Metric | Axis · Direct · IDCW NAV ₹9.77 Very High risk ★★☆☆☆ 1Y | Category median Sectoral/ Thematic · 250 funds |
|---|---|---|
| -1.91% | +5.11% | |
| — | +13.02% | |
| — | +11.14% | |
| — | +12.26% | |
| -1.61% | +11.82% | |
| +3.67% | — | |
| — | +14.62% | |
| — | +12.95% | |
| — | +13.24% | |
| Risk | ||
| 13.99% | 15.88% | |
| -0.60 | 0.35 | |
| -0.81 | 0.47 | |
| -20.10% | -25.18% | |
| Nifty 500 | — | |
| — | +1.40% | |
| — | 0.98 | |
| — | 101.5% | |
| — | 97.0% | |
| 0.85% | 1.14% | |
| ₹2,796Cr | ₹1,162Cr | |
| Up to 1.00% | — | |
| None | — | |
| ₹500 | — | |
| ₹100 | — | |
| 29% | 45% | |
| Krishnaa Narayan | — | |
| 18 Sep 2024 | — | |
| 57 | — | |
| 51.8% | — | |
| -0.2% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.